TACTILE SYSTEMS TECHNOLOGY INC TCMD

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Tactile Systems Technology, Inc. ("we," "us," and "our") is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. and in September 2013, we began doing business as "Tactile Medical".

Our mission is to help people suffering from chronic diseases live better and care for themselves at home. We focus our efforts on advancing the standard of care in treating underserved chronic diseases in the home to improve patient outcomes and quality of life and help control rising healthcare expenditures. Our areas of therapeutic focus are (1) vascular disease, with a goal of advancing the standard of care in treating lymphedema and chronic venous insufficiency, (2) oncology, where lymphedema is a common consequence among cancer survivors and (3) providing airway clearance therapy for those suffering from chronic respiratory conditions. We possess a unique, scalable platform to deliver at-home healthcare solutions throughout the United States. This evolving home care delivery model is recognized by policymakers and insurance payers as a key for controlling rising healthcare costs. Our solutions deliver cost-effective, clinically proven, long-term treatment for people with these chronic diseases.

Last close 23.64 2026-10-23
Market cap $535.5M 2026-06-30 share count
52-week range 14.84 - 37.77

Valuation FY2025 figures against the last close

P/S1.6x
P/E28.8x
P/FCF13.2x
EV/EBITDA12.6x
Dividend yield—
Diluted EPS0.82

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $329.5M$293.0M$274.4M$246.8M$208.1M$187.1M$189.5M$143.8M$109.3M$84.5M
Cost of revenue $79.4M$76.3M$79.3M$70.8M$59.8M$54.3M$55.3M$41.5M$29.0M$22.9M
Gross profit $250.1M$216.7M$195.1M$176.0M$148.2M$132.8M$134.2M$102.3M$80.3M$61.6M
R&D $8.5M$8.8M$7.8M$7.1M$5.7M$5.3M$5.2M$5.3M$5.1M$4.5M
SG&A $88.7M$71.1M$62.1M$60.8M$56.8M$51.3M$39.5M$33.6M$26.9M$19.1M
Total operating expenses $220.9M$194.5M$177.1M$188.7M$150.0M$136.4M$123.7M$99.3M$76.4M$57.3M
Operating income $29.3M$22.2M$18.0M-$12.8M-$1.8M-$3.6M$10.5M$3.0M$3.9M$4.3M
Interest expense $1.0M$2.1M$4.1M$2.8M——————
Pre-tax income $31.3M$23.5M$15.8M-$15.5M-$2.3M-$2.3M$11.1M$3.5M$4.2M$4.3M
Income tax $12.3M$6.5M$12.7M$2.4M$9.5M$1.6M$158.0K$3.1M$1.7M$1.4M
Net income $19.1M$17.0M$28.5M-$17.9M-$11.8M-$620.0K$11.0M$6.6M$5.9M$2.9M
EPS, basic 0.830.711.24-0.89-0.60-0.030.580.360.340.18
EPS, diluted 0.820.701.23-0.89-0.60-0.030.560.340.310.15
Shares, diluted (wtd. avg.) 23.3M24.1M23.2M20.1M19.7M19.3M19.6M19.3M18.9M10.8M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $83.4M$94.4M$61.0M$21.9M$28.2M$47.9M$22.8M$20.1M$24.0M$30.7M
Short-term investments —————$0$22.5M$25.8M$19.9M$11.0M
Receivables $43.9M$44.9M$43.2M$54.8M$49.5M$43.8M$33.4M$24.3M$17.6M$15.0M
Inventory $14.0M$18.7M$22.5M$23.1M$19.2M$18.6M$19.1M$11.2M$11.0M$6.6M
Total current assets $165.2M$177.6M$145.3M$119.8M$113.5M$123.6M$108.3M$85.0M$76.9M$64.2M
Property, plant and equipment $5.1M$5.6M$6.2M$6.1M$6.8M$7.0M$7.4M$4.8M$3.8M$1.6M
Goodwill $31.1M$31.1M$31.1M$31.1M$31.1M—————
Other intangibles $39.2M$42.8M$46.7M$50.4M$53.5M$1.7M$5.3M$5.3M$2.2M—
Total assets $273.9M$297.9M$281.4M$255.0M$244.3M$174.1M$151.8M$107.1M$88.4M$73.9M
Accounts payable $5.0M$5.6M$6.7M$10.0M$5.0M$4.2M$3.8M$5.1M$4.3M$3.8M
Total current liabilities $41.0M$40.7M$41.1M$64.3M$34.5M$26.7M$21.4M$16.1M$14.5M$13.8M
Long-term debt $0—$16.8M———————
Total liabilities $55.0M$81.3M$87.8M$133.6M$116.0M$49.3M$39.2M$17.8M$15.7M$14.3M
Retained earnings $54.9M$35.9M$18.9M-$9.6M$8.2M$20.1M$20.7M$9.7M$3.1M-$2.8M
Total equity $218.9M$216.6M$193.6M$121.4M$128.2M$124.8M$112.6M$89.3M$72.8M$59.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $42.8M$40.7M$35.9M$5.2M$2.6M$2.8M$2.5M$9.0M$4.2M$7.0M
Depreciation and amortisation $6.6M$6.8M$6.5M$6.3M$3.7M$2.8M$3.5M$3.7M$1.8M$799.0K
Stock-based compensation $8.4M$7.8M$7.5M$9.6M$10.2M$10.7M$9.8M$8.0M$4.2M$1.9M
Capital expenditure $2.4M$2.4M$2.3M$1.8M$2.1M$2.1M$5.4M$4.2M$3.7M$775.0K
Investing cash flow -$2.5M-$2.5M-$2.5M-$1.9M-$82.2M$20.2M-$2.3M-$14.7M-$14.0M-$11.8M
Financing cash flow -$51.2M-$4.8M$5.7M-$9.6M$59.9M$2.1M$2.5M$1.9M$3.1M$28.5M
Buybacks $26.6M$3.5M——————$493.0K—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-016380.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -100M 0 100M 200M 300M 400M Revenue, FY2016: 84.5M Gross profit, FY2016: 61.6M Net income, FY2016: 2.9M Revenue, FY2017: 109.3M Gross profit, FY2017: 80.3M Net income, FY2017: 5.9M Revenue, FY2018: 143.8M Gross profit, FY2018: 102.3M Net income, FY2018: 6.6M Revenue, FY2019: 189.5M Gross profit, FY2019: 134.2M Net income, FY2019: 11M Revenue, FY2020: 187.1M Gross profit, FY2020: 132.8M Net income, FY2020: -620K Revenue, FY2021: 208.1M Gross profit, FY2021: 148.2M Net income, FY2021: -11.8M Revenue, FY2022: 246.8M Gross profit, FY2022: 176M Net income, FY2022: -17.9M Revenue, FY2023: 274.4M Gross profit, FY2023: 195.1M Net income, FY2023: 28.5M Revenue, FY2024: 293M Gross profit, FY2024: 216.7M Net income, FY2024: 17M Revenue, FY2025: 329.5M Gross profit, FY2025: 250.1M Net income, FY2025: 19.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $84.5M $109.3M $143.8M $189.5M $187.1M $208.1M $246.8M $274.4M $293.0M $329.5M
Gross profit $61.6M $80.3M $102.3M $134.2M $132.8M $148.2M $176.0M $195.1M $216.7M $250.1M
Net income $2.9M $5.9M $6.6M $11.0M -$620.0K -$11.8M -$17.9M $28.5M $17.0M $19.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%